Investor Presentaiton
Company overview
Financial performance
Oncology
Financial review
2022 priorities
Appendix
Innovation: Pipeline overview
Innovation: Clinical trials
Immunology
Ophthalmology
Neuroscience
Respiratory Disease
Scemblix® - BCR-ABL inhibitor
NCT04971226 ASC4FIRST (CABL001J12301)
Indication
Chronic myeloid leukemia, 1st line
Phase 3
Phase
Patients
402
Primary
Outcome
Measures
Arms
Intervention
Major Molecular Response (MMR) at week 48
Arm 1: asciminib 80 mg QD
Arm 2: Investigator selected TKI including one of the below treatments:
- Imatinib 400 mg QD
- Nilotinib 300 mg BID
- Dasatinib 100 mg QD
- Bosutinib 400 mg QD
Patients with newly diagnosed philadelphia chromosome positive chronic
myelogenous leukemia in chronic phase
2024
Target
Patients
Read-out
Milestone(s)
Publication
TBD
62 Investor Relations | Q2 2022 Results
References
Abbreviations
Cardio-Renal
Global Health
Biosimilars
NOVARTIS | Reimagining MedicineView entire presentation